

NICHOLAS F. COSCIA, ESQ.

Attorney at Law
P.O. Box 789
Cardiff-by-the-Sea, CA 92007
(619) 993-3361
Email: Nick@CosciaSEC.com

April 29, 2017

OTC Markets Group, Inc.
304 Hudson Street, Second Floor
New York, NY 10013

Re: Balincan USA, Inc.

Ladies and Gentlemen:

Balincan USA, Inc., F/K/A Moqizone Holdings Corporation, a Delaware corporation, (the "Issuer"), has requested our opinion with respect to the Reports publicly disclosed by the Issuer and published in the OTC Disclosure and News Service on April 13, 2017, for the annual financial reporting period ending December 31, 2016. This opinion is solely for the information of the addressee hereof and OTC Markets Group, Inc. is entitled to rely on such letter in determining whether the Issuer has made adequate current financial information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. The undersigned grants OTC Markets Group, Inc. full and complete permission and right to publish the letter in the OTC Disclosure and News Service for viewing by the public and regulators.

The undersigned is a U.S. resident and was retained by the Issuer for, among other things, the purpose of rendering this opinion and related matters. We currently serve as outside general counsel and regular disclosure counsel for the Issuer. This opinion is based on our knowledge of the law and facts as of the date hereof. The undersigned has examined such corporate records and other documents and such questions of law as deemed appropriate for the purposes of rendering this opinion.

The undersigned was admitted to the Bar of the State of California in 1979. The undersigned is permitted to practice before the Securities and Exchange Commission ("SEC") and has never been barred from practice in either of the foregoing jurisdictions.

In rendering the legal opinion contained in this letter, we have reviewed certain documents and information furnished by the Issuer including but not limited to the Issuer's Articles of Incorporation, Bylaws, and Minutes of directors meetings and directors consents reflecting actions of its Board of Directors and such other documents as we deemed relevant and necessary as a basis for the opinion hereinafter set forth. In such examinations, we have assumed the genuineness of all signatures set forth on each document, the authenticity of all original documents and the conformity to original documents of all copies of such documents as may have been supplied to us during the course of our examination.

For the purposes of rendering this opinion, we have assumed that no person or entity has engaged in fraud or misrepresentation regarding the inducement relating to, or the execution or delivery of, the documents reviewed. Furthermore, we express no opinion as to the validity of any assumptions, form or content of any financial or statistical data contained therein. The terms used in this opinion shall have the meaning ascribed to them in the documents relied upon in rendering our opinion.

Regarding the common stock of the Issuer, \$0.001 par value (the "Securities"), in the opinion of the undersigned, the Unaudited Financial Statements and footnotes thereto, Management's Discussion and Analysis of Financial Condition and Results of Operations and Supplemental Disclosure for the fiscal year ended December 31, 2016, all of which have been published on the OTC Disclosure and News Service on April 13, 2017 (i) constitute "adequate current public information" concerning the Securities of the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act of 1933, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) comply as to form with the Pink Sheets Guidelines for Providing Adequate Current Public Information, which are located on the Internet at www.otcmarkets.com, and (iv) have been posted in the OTC Disclosure and News Service. Furthermore, after reasonable investigation, I have no reason to believe that such information contained any untrue statement of a material fact or omitted to state a material fact in order to make the statements made, in light of the circumstances under which they were made, not misleading.

The unaudited Financial Statements and Footnotes thereto set forth in the preceding paragraph were prepared by Company management supervised by its financial comptroller with significant experience in preparation of periodic reports for publicly traded companies.

The Company's transfer agent is VStock Transfer, which is registered with the SEC. We have reviewed a copy of the certified shareholder list prepared by the transfer agent as of March 17, 2017, to confirm that the number of outstanding shares set forth in the Information is correct.

The undersigned has (i) met on multiple occasions with the Issuer's management and both of its directors, (ii) reviewed the Information published by the Issuer on the OTC Disclosure and News Service, and (iii) discussed the Information with management and both of the directors of the Issuer. To the best of our knowledge, and after reasonable inquiry of the Issuer's management and directors, there is no officer, director, 5% holder, or counsel currently under

OTC Markets Group, Inc.

April 29, 2017


Page 3

investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

This opinion is solely for the information of the addressee hereof and the other parties specifically identified in the first paragraph hereof, and is not to be quoted in whole or in part or otherwise referred to, nor is it to be filed with any governmental agency or other person without our prior written consent. Other than the addressee hereof and such other identified parties, no one is entitled to rely on this opinion. This opinion is based on our knowledge of the law and facts as of the date hereof. We assume no duty to communicate with you with respect to any matter which comes to our attention hereafter.

If you have any questions or comments with respect to any of the foregoing, please do not hesitate to contact me.

Very truly yours,

A handwritten signature in blue ink, appearing to read 'NFC', is written over the typed name below.

Nicholas F. Coscia, Esq.

NFC:kmm